When the Rapid Initiation of Nasal Saline Irrigation (RINSI) study — a randomized clinical trial conducted by Augusta University — was published in the Ear, Nose and Throat Journal in 2022, it produced a number that stopped researchers in their tracks. High-risk adults aged 55 and older who began nasal irrigation within 24 hours of a positive COVID-19 test were eight times less likely to be hospitalized than the national CDC rate for their age group.

That's not a statistical footnote. That's a finding with real, actionable implications — and what's more, the RINSI researchers themselves were clear that the underlying mechanism extends well beyond any single virus.

Why the nose is the front line of every respiratory illness

The mechanism isn't COVID-specific; it's anatomical. Virtually every respiratory virus — from the common cold to influenza to coronaviruses — enters the body through the nasal passages. The nose isn't just a breathing organ; it's the primary gateway through which pathogens reach the respiratory tract and, eventually, the lungs.

The RINSI researchers noted that nasal irrigation under pressure has been shown to reduce both the duration and severity of illness caused by coronaviruses and influenza-type infections alike. Which is why the RINSI protocol specifically called for starting nasal irrigation within 24 hours of first symptoms, before viral replication can gain momentum. Naväge, one of only two devices named by brand in the RINSI trial, and the only powered suction system among them, is built around exactly this mechanism.

Not all nasal rinses are created equal

The RINSI trial named two devices by brand: NeilMed Sinus Rinse and Naväge. Of the two, Naväge is the only powered, suction-based nasal irrigation system in the study, and the only one of its kind to appear in peer-reviewed clinical research of this scope.

This distinction matters mechanically. Traditional squeeze bottles like NeilMed rely on gravity and manual pressure to move saline through the nasal cavity. Naväge's patented powered suction technology is fundamentally different: it creates a controlled, through-the-nose flow — the same deep-cleaning action that reaches where sprays can't, and the specific mechanical approach the RINSI protocol utilized. Unlike steroid sprays that can take hours to work,^* Naväge delivers fast, drug-free congestion relief by physically removing blockages.

What this means for your health routine year-round

Flu season. Cold season. The back-to-school surge in September. Each represents the same underlying threat: a respiratory virus entering through the nose, replicating, and progressing. The RINSI study's findings suggest that acting within that first 24-hour window can meaningfully shift outcomes — not just during a pandemic, but across any viral season.

For those already using nasal irrigation for allergies or sinus relief, the RINSI findings offer a compelling reason to reach for it at the very first sign of illness. For those new to nasal rinsing, this trial represents some of the strongest peer-reviewed evidence to date that it belongs in your toolkit.

The bottom line

The RINSI study represents some of the strongest peer-reviewed evidence to date for early nasal irrigation as an adjunct to respiratory illness management. Naväge is one of only two brands named in that research, and the only powered suction device in the trial. For anyone looking to act on what this research shows, choosing the device the RINSI researchers actually used — backed by ENT physicians^§ and over 100,000 five-star reviews — is a logical step toward better respiratory wellness.

Common questions about the RINSI study

This article is based on the RINSI (Rapid Initiation of Nasal Saline Irrigation) Study, a randomized clinical trial conducted by Augusta University, published in the Ear, Nose and Throat Journal in 2022 (DOI: 10.1177/01455613221123737). It is intended for general informational purposes and does not constitute medical advice. Consult a healthcare provider with questions about nasal irrigation or respiratory illness management.